Quick Answer
Humacyte, Inc. reported Net Income Loss of -$40.83 million for the year ending 2025.
- Humacyte, Inc. showed an increase of +72.5% in Net Income Loss from 2024 to 2025.
- This data is from Humacyte, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$17.67 million | Q2 2020: -$14.88 million | Q3 2020: -$17.76 million | Q1 2021: -$20.30 million | Q2 2021: -$17.20 million | Q3 2021: -$31.56 million | Q1 2022: -$19.83 million | Q2 2022: $36.87 million | Q3 2022: -$25.28 million | Q1 2023: -$36.97 million | Q2 2023: -$22.71 million | Q3 2023: -$26.00 million | Q1 2024: -$31.90 million | Q2 2024: -$56.66 million | Q3 2024: -$39.20 million | Q1 2025: $39.14 million | Q2 2025: -$37.66 million | Q3 2025: -$17.51 million.
- Over the full 6 years of available data (2020 to 2025), Humacyte, Inc.'s Net Income Loss has grown by 38.6%.
- Historical annual values: Fiscal year 2025: -$40.83 million | Fiscal year 2024: -$148.70 million | Fiscal year 2023: -$110.78 million | Fiscal year 2022: -$11.97 million | Fiscal year 2021: -$26.48 million | Fiscal year 2020: -$66.52 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: